JP2011513438A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011513438A5 JP2011513438A5 JP2010550004A JP2010550004A JP2011513438A5 JP 2011513438 A5 JP2011513438 A5 JP 2011513438A5 JP 2010550004 A JP2010550004 A JP 2010550004A JP 2010550004 A JP2010550004 A JP 2010550004A JP 2011513438 A5 JP2011513438 A5 JP 2011513438A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl
- aryl
- alkoxy
- halo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 297
- 125000003545 alkoxy group Chemical group 0.000 claims description 165
- 125000003118 aryl group Chemical group 0.000 claims description 165
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 132
- 125000001475 halogen functional group Chemical group 0.000 claims description 132
- 125000001072 heteroaryl group Chemical group 0.000 claims description 132
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 132
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 claims description 132
- 229910052736 halogen Inorganic materials 0.000 claims description 99
- 150000002367 halogens Chemical class 0.000 claims description 99
- 125000001424 substituent group Chemical group 0.000 claims description 99
- 125000003282 alkyl amino group Chemical group 0.000 claims description 66
- 229910052757 nitrogen Inorganic materials 0.000 claims description 66
- 206010028980 Neoplasm Diseases 0.000 claims description 54
- 150000001875 compounds Chemical class 0.000 claims description 44
- 150000003839 salts Chemical class 0.000 claims description 43
- 125000003342 alkenyl group Chemical group 0.000 claims description 33
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 33
- 125000004414 alkyl thio group Chemical group 0.000 claims description 33
- 125000002947 alkylene group Chemical group 0.000 claims description 33
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 33
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 33
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 33
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 33
- 125000001841 imino group Chemical group [H]N=* 0.000 claims description 33
- 125000000449 nitro group Chemical class [O-][N+](*)=O 0.000 claims description 33
- 229910052760 oxygen Inorganic materials 0.000 claims description 33
- 239000001301 oxygen Substances 0.000 claims description 33
- 201000011510 cancer Diseases 0.000 claims description 27
- 239000002246 antineoplastic agent Substances 0.000 claims description 20
- 229940127089 cytotoxic agent Drugs 0.000 claims description 20
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 18
- 206010006187 Breast cancer Diseases 0.000 claims description 18
- 208000026310 Breast neoplasm Diseases 0.000 claims description 18
- 208000029742 colonic neoplasm Diseases 0.000 claims description 18
- 208000020816 lung neoplasm Diseases 0.000 claims description 18
- 230000002401 inhibitory effect Effects 0.000 claims description 13
- 206010009944 Colon cancer Diseases 0.000 claims description 12
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 12
- 230000034994 death Effects 0.000 claims description 12
- 201000005202 lung cancer Diseases 0.000 claims description 12
- RMYZIRFUCOMQRH-UHFFFAOYSA-N n-[1-(2-fluorophenyl)pyrazol-3-yl]-1'-oxospiro[cyclohexane-4,3'-furo[3,4-c]pyridine]-1-carboxamide Chemical compound FC1=CC=CC=C1N1N=C(NC(=O)C2CCC3(CC2)C2=CN=CC=C2C(=O)O3)C=C1 RMYZIRFUCOMQRH-UHFFFAOYSA-N 0.000 claims description 11
- 230000004614 tumor growth Effects 0.000 claims description 11
- 206010060862 Prostate cancer Diseases 0.000 claims description 9
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 9
- 201000009030 Carcinoma Diseases 0.000 claims description 8
- 230000001939 inductive effect Effects 0.000 claims description 8
- 208000037841 lung tumor Diseases 0.000 claims description 6
- 208000023958 prostate neoplasm Diseases 0.000 claims description 6
- 230000033115 angiogenesis Effects 0.000 claims description 5
- 206010005003 Bladder cancer Diseases 0.000 claims description 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
- 206010014733 Endometrial cancer Diseases 0.000 claims description 4
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 4
- 201000008808 Fibrosarcoma Diseases 0.000 claims description 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 4
- 206010025323 Lymphomas Diseases 0.000 claims description 4
- 206010029260 Neuroblastoma Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 206010038389 Renal cancer Diseases 0.000 claims description 4
- 206010039491 Sarcoma Diseases 0.000 claims description 4
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 4
- 201000006491 bone marrow cancer Diseases 0.000 claims description 4
- 201000010881 cervical cancer Diseases 0.000 claims description 4
- 230000003511 endothelial effect Effects 0.000 claims description 4
- 201000010982 kidney cancer Diseases 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 4
- 201000000849 skin cancer Diseases 0.000 claims description 4
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 4
- 206010012646 Diabetic blindness Diseases 0.000 claims description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 3
- 201000004681 Psoriasis Diseases 0.000 claims description 3
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 3
- 230000006907 apoptotic process Effects 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 208000002780 macular degeneration Diseases 0.000 claims description 3
- 230000001404 mediated effect Effects 0.000 claims description 3
- 210000002307 prostate Anatomy 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 201000000306 sarcoidosis Diseases 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 125000002252 acyl group Chemical group 0.000 claims 10
- 125000001589 carboacyl group Chemical group 0.000 description 56
- 238000000034 method Methods 0.000 description 34
- 239000003814 drug Substances 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 0 C[U]=*C(C(CC1)(CC*1C(N*)=O)*C(C1)=O)=C1*=C Chemical compound C[U]=*C(C(CC1)(CC*1C(N*)=O)*C(C1)=O)=C1*=C 0.000 description 5
- 101000633401 Homo sapiens Neuropeptide Y receptor type 5 Proteins 0.000 description 4
- 102100029549 Neuropeptide Y receptor type 5 Human genes 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 150000003857 carboxamides Chemical class 0.000 description 2
- 230000014399 negative regulation of angiogenesis Effects 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6890008P | 2008-03-11 | 2008-03-11 | |
| US61/068,900 | 2008-03-11 | ||
| US12690908P | 2008-05-08 | 2008-05-08 | |
| US61/126,909 | 2008-05-08 | ||
| US19035608P | 2008-08-28 | 2008-08-28 | |
| US61/190,356 | 2008-08-28 | ||
| US11823108P | 2008-11-26 | 2008-11-26 | |
| US61/118,231 | 2008-11-26 | ||
| PCT/CA2009/000286 WO2009111868A1 (en) | 2008-03-11 | 2009-03-10 | Method of treating cancer using a neuropeptide y 5r (np y5r) antagonist |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011513438A JP2011513438A (ja) | 2011-04-28 |
| JP2011513438A5 true JP2011513438A5 (enExample) | 2012-04-19 |
| JP5593234B2 JP5593234B2 (ja) | 2014-09-17 |
Family
ID=41064694
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010550004A Expired - Fee Related JP5593234B2 (ja) | 2008-03-11 | 2009-03-10 | ニューロペプチドｙ５ｒ（ｎｐｙ５ｒ）アンタゴニストを使用して癌を治療する方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8765791B2 (enExample) |
| EP (1) | EP2262499B1 (enExample) |
| JP (1) | JP5593234B2 (enExample) |
| CN (1) | CN102014900B (enExample) |
| AU (1) | AU2009225189B2 (enExample) |
| CA (1) | CA2717904C (enExample) |
| WO (1) | WO2009111868A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5629752B2 (ja) | 2009-04-06 | 2014-11-26 | ユニバーシティ・ヘルス・ネットワークＵｎｉｖｅｒｓｉｔｙ Ｈｅａｌｔｈ Ｎｅｔｗｏｒｋ | キナーゼインヒビターおよびこれを用いた癌の治療方法 |
| SI2556071T1 (sl) | 2010-04-06 | 2016-12-30 | University Health Network | Kinazni inhibitorji in njihova uporaba pri zdravljenju raka |
| WO2013101617A1 (en) * | 2011-12-29 | 2013-07-04 | Purdue Research Foundation | Method for assessing a liver of a patient having a chronic hepatitis b virus infection |
| WO2015054781A1 (en) | 2013-10-18 | 2015-04-23 | University Health Network | Treatment for pancreatic cancer |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2016921B (en) * | 1978-03-27 | 1982-08-18 | Taiho Pharmaceutical Co Ltd | Anti cancer compositions containing uracil derivatives |
| TWI279402B (en) | 1999-08-20 | 2007-04-21 | Banyu Pharma Co Ltd | Spiro compounds having NPY antagonistic activities and agents containing the same |
| AU2001264376A1 (en) | 2000-06-15 | 2001-12-24 | Chaconne Nsi Co., Ltd. | Urea derivative useful as an anti-cancer agent and process for preparing same |
| US6806272B2 (en) | 2001-09-04 | 2004-10-19 | Boehringer Ingelheim Pharma Kg | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions |
| JP3876254B2 (ja) | 2001-09-04 | 2007-01-31 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | 新規なジヒドロプテリジノン、その製造方法及びその医薬組成物としての使用 |
| JP2005533849A (ja) * | 2002-07-18 | 2005-11-10 | メルク エンド カムパニー インコーポレーテッド | 肥満治療のための組み合わせ療法 |
| EP1635832A2 (en) | 2003-06-06 | 2006-03-22 | Merck & Co., Inc. | Combination therapy for the treatment of diabetes |
| US20050288279A1 (en) * | 2004-06-24 | 2005-12-29 | Rozman Karl K | Phenothiazine derivatives and their method of use |
| EP1968979A2 (en) | 2005-12-08 | 2008-09-17 | Abbott Laboratories | 9-membered heterobicyclic compounds as inhibitors of protein kinases |
-
2009
- 2009-03-10 JP JP2010550004A patent/JP5593234B2/ja not_active Expired - Fee Related
- 2009-03-10 US US12/921,959 patent/US8765791B2/en active Active
- 2009-03-10 EP EP09720807.8A patent/EP2262499B1/en not_active Not-in-force
- 2009-03-10 AU AU2009225189A patent/AU2009225189B2/en not_active Ceased
- 2009-03-10 CN CN200980115801.XA patent/CN102014900B/zh not_active Expired - Fee Related
- 2009-03-10 CA CA2717904A patent/CA2717904C/en not_active Expired - Fee Related
- 2009-03-10 WO PCT/CA2009/000286 patent/WO2009111868A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7058345B2 (ja) | Ｂｃｌ－２阻害剤及びＭＤＭ２阻害剤の組合せ製品並びに疾患の予防及び／又治療におけるその使用 | |
| JP3835763B2 (ja) | 増殖亢進疾患のための組み合わせ治療 | |
| JP2017517548A5 (enExample) | ||
| JP2012233015A (ja) | ジアザベンゾ［デ］アントラセン−３−オン化合物、及び、ｐａｒｐの阻害方法 | |
| JP2010523696A (ja) | 脳腫瘍を治療する方法 | |
| JPWO2020260252A5 (enExample) | ||
| CN107666906A (zh) | 用于治疗癌症的方法 | |
| WO2016069392A1 (en) | Administration of ubiquitin-activating enzyme inhibitor and chemotherapeutic agents | |
| JP2018510154A (ja) | 癌の新治療法 | |
| JP2011513438A5 (enExample) | ||
| TW201811323A (zh) | 抗腫瘤劑、抗腫瘤效果增強劑及抗腫瘤用套組 | |
| JP6913955B2 (ja) | ＰＩ３Ｋ／ｍＴＯＲ阻害剤としての溶融キノリン化合物 | |
| CA3011289A1 (en) | Compounds for inhibiting cancer and virus | |
| CN103965175A (zh) | 4-(取代苯氨基)喹唑啉类化合物、其制备方法及应用 | |
| CN105209032A (zh) | 使用转录因子调节剂治疗癌症和其他病症 | |
| CN103755695A (zh) | 一种具有抗肿瘤活性的酰胺类化合物及其应用 | |
| EP3492082B1 (en) | Anticancer pharmaceutical composition | |
| CN1879619A (zh) | 癌症治疗 | |
| US11390601B2 (en) | Conformationally-restricted analogues of sorafenib and regorafenib as selective kinase inhibitors for cancer treatment | |
| CN1678310A (zh) | 用于治疗良性和恶性肿瘤疾病的含有disorazole及其衍生物的药物 | |
| WO2025083568A1 (en) | Novel small-molecule protein kinase inhibitors for implications in cancer treatment | |
| EP3452447A1 (en) | Inhibitors of ires-mediated protein synthesis | |
| WO2023126980A1 (en) | Mercaptopyrimidine compounds that inhibit nonhomologous end joining and methods thereof | |
| WO2025083563A1 (en) | Effective therapeutic small-molecule inhibitors for metastatic cancer | |
| WO2025083564A1 (en) | Novel small molecule degrader as a potential anticancer |